Antisense Therapeutics Limited announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during third quarter current year 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.068 AUD | +6.25% | -6.85% | +15.25% |
Feb. 28 | Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
2023 | Dimerix Appoints Nonexecutive Chair | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.25% | 39.98M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PER Stock
- News Percheron Therapeutics Limited
- Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK